Comparison of apolipoprotein B and non-high-density lipoprotein cholesterol for identifying coronary artery disease risk based on receiver operating curve analysis

American Journal of Clinical Pathology

Volumn 127, Issue 3, 2007, Pages 449-455

  Levinson, Stanley S ^a,b  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein B; Coronary risk; Low density lipoprotein cholesterol; Non high density lipoprotein cholesterol; Receiver operating characteristic curves; Relative risk and odds ratios

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL DERIVATIVE; LIPID; LIPOPROTEIN; NONHIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; RISK FACTOR; ROC CURVE;

ADULT; AGED; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS; ROC CURVE; TRIGLYCERIDES;

EID: 34247844419     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/22M22RF48PX9UT9T     Document Type: Article

References (25)

1. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 1995;332:1491-1498.
2. Sniderman AD, Clanflone K. Measurement of apolipoproteins: time to improve the diagnosis and treatment of atherogenic dyslipoproteinemias [editorial]. Clin Chem. 1996;42:489-491.
3. Lamarche B, Tchernof A, Mauiége P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 1998;279:1955-1961.
4. Levinson SS. High density- and beta-lipoprotein screening for risk of coronary artery disease in the context of new findings associated with reverse cholesterol transport. Ann Clin Lab Sci. 2002;32:123-136.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
6. Levinson SS, Wagner S. Immunonephelometric/turbidimetric apolipoprotein B assays for the clinical laboratory. Clin Chim Acta. 1993;223:31-42.
7. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106:2526-2529.
8. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326-333.
9. Sattar N, Williams K, Sniderman AD, et al. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004;110:2687-2693.
10. Simon A, Chironi G, Gariepy J, et al. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis. 2005;179:339-344.
11. Pischon T, Girman CJ, Sacks FM, et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375-3383.
12. Harris N, Galpchian V, Rifai N. Three routine methods for measuring high-density lipoprotein cholesterol compared with the reference method. Clin Chem. 1996;42:738-743.
13. Maciejko JJ, Levinson SS, Markyvech L, et al. Evaluation of a new method for assaying apo A-I and apo B lipoproteins by rate nephelometry. Clin Chem. 1987;11:2065-2069.
14. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
15. Zweig MH, Broste SK, Reinhart RA. ROC curve analysis: an example showing the relationships among serum lipid and apolipoprotein concentrations in identifying patients with coronary artery disease. Clin Chem. 1992;38:1425-1428.
16. Zweig MH, Campbell C. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-577.
17. Aguilar Salinas CA, Zamora M, Gomez-Diaz RA, et al. Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis. Semin Vasc Med. 2004;4:203-209.
18. Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is... [editorial]. Circulation. 2005;112:3366-3367.
19. Denke MA. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation. 2005;112:3368-3370.
20. Grover SA, Coupal L, Xiao-Ping H. Identifying adults at increased risk of coronary artery disease. JAMA. 1995;274:801-806.
21. St-Pierre AC, Cantin B, Bergeron J, et al. Inflammatory markers and long-term risk of ischemic heart disease in men: a 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis. 2005;182:315-321.
22. Stewart BF, Brown BG, Zhao XQ, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol. 1994;23:899-906.
23. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343:75-79.
24. Austin MA, King MC, Vranizan KM, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease. Circulation. 1990;82:495-506.
25. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS Study): a prospective study. Lancet. 2001;358:2026-2033.